Recent News

• 05.28.2025 - Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
• 05.13.2025 - Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
• 05.06.2025 - Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
• 05.05.2025 - Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
• 05.01.2025 - Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
• 04.24.2025 - Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
• 04.23.2025 - Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
• 04.21.2025 - Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
• 04.14.2025 - Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Recent Filings

• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2025 - 424B4 Prospectus [Rule 424(b)(4)]
• 05.06.2025 - EX-99.1 EX-99.1
• 05.06.2025 - 8-K Current report
• 05.05.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.05.2025 - 8-K Current report
• 05.02.2025 - 424B4 Prospectus [Rule 424(b)(4)]
• 04.29.2025 - EFFECT Notice of Effectiveness
• 04.23.2025 - S-3 Registration statement under Securities Act of 1933
• 04.17.2025 - 8-K Current report